CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development

Advanced insights from CytoReason’s disease models will support Pfizer’s drug development process

CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs.

AI and ML News: Why SMBs Shouldn’t Be Afraid of Artificial Intelligence (AI)

Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years.

Since launching the collaboration in 2019, Pfizer has used CytoReason’s biological models in its research to enhance the understanding of the immune system, as it develops innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason’s platform has provided Pfizer with multiple insights in research and development programs across over 20 diseases.

The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.

“We’re pleased to expand our strategic collaboration with CytoReason,” said Mikael Dolsten, Chief Scientific Officer and President, Pfizer. “We look forward to continuing our work with the company’s leading scientists, and to leveraging its cutting-edge platform. CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective.”

Read More About AI News : Role of AI in Helping B2B companies that are Missing Out on Buyer Intent Data

CytoReason has established itself as a global leader in computational modeling of human diseases thanks to its unique ability to combine computational models, proprietary human data, and the AI tools needed to provide actionable insights for accelerating drug development. The company’s multidisciplinary team of 80 leading biologists, bioinformaticians and data engineers has developed a platform that enables pharmaceutical and biotech companies to prioritize new targets, find biomarkers, and predict which patients may best respond to novel treatments.

“Pfizer has been a strategic partner of CytoReason since 2019, and we are thrilled to scale our collaboration as one of Pfizer’s trusted AI partners for accelerating drug development,” said David Harel, CEO and Co-founder of CytoReason. “This partnership is advancing a significant shift in the biotech industry, and helping drive future R&D for pharmaceutical companies as they continue to use machine learning to develop treatments more efficiently. Transforming complex data into useful actionable insights will potentially provide leading researchers and scientists a roadmap to further develop their drug portfolios.”

CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies can identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. To date, five of the world’s top ten pharma companies use CytoReason’s technology

Future of AI-driven Customer Relationship:  Microsoft’s Viva Sales and the Future of AI-driven Customer Relationship and Experience Management

[To share your insights with us, please write to sghosh@martechseries.com]